Looking for new assets in advanced research or preclinical development stages that could be useful for the treatment of dermatological diseases

Summary

A Spanish pharmaceutical company active in the skin care sector is looking for partnering opportunities on new assets in advanced research or preclinical development stages that could be useful for the treatment of dermatological diseases within the frame of a research cooperation agreement or a technical cooperation agreement. This request refers to an open innovation challenge.

Description

A Spanish pharmaceutical company developing breakthrough innovative products in the field of dermatology to address patients’ unmet needs has launched an open innovation challenge.

They are looking for partnering opportunities on new assets in advanced research or preclinical development stages that could be useful for the treatment of skin diseases.

Preferably, the solution sought should: target immuno-inflammatory pathways or be suitable for dermato-oncological or rare dermatological indications, involve any therapeutic modality and demonstrate strong evidences of efficacy.

The aim of the company is to explore the possibility to establish a long-term business partnership under the frame of a research cooperation agreement or a technical cooperation agreement. Within this collaboration, the Spanish company is looking for:
- Collaborate in the development of new assets in advanced research or preclinical stage
- Apply to research grants
- Characterise further assets in a pre-agreed panel of relevant cellular assays and in vivo models for dermatological diseases

IMPORTANT:
This technology request refers to an innovation challenge published on an online open innovation platform from July 5th, 2021 to October 31st, 2021. Organizations are invited to express their interest using the platform (a secure site to store and manage the proposals) after creating there an account. All the initial information provided under the proposal should be non-confidential. Sharing of confidential information will be made possible on demand. A designated contact person of the Spanish Company will help the interested entity on answering any question

Proposal evaluation and selection:
o A team of Company’s scientific experts will evaluate the proposal as soon as it is received
o The participant will receive in writing their decision regarding the proposal within 8 -10 weeks after submission
o If the proposal has been selected, a member of the Company’s Team will contact the entity behind it to initiate a partnership agreement that will reflect a collaborative proposal, including eventual experimental activities, and/or a business proposal according to the asset’s development stage

Technical Specification or Expertise Sought

Preferably, the assets should: - Target immuno-inflammatory pathways or be suitable for dermato-oncological or rare dermatological indications - Involve any therapeutic modality such as small molecules, biologics or advanced therapies - Demonstrate strong scientific rationale, including in vitro and in vivo evidences of efficacy, if available

Contact/ source: Enterprise Europe Network (europa.eu)